ROS1ders Blog

What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More

What is Targeted Therapy?

Confused about 1st and 2nd line drugs? Here’s a guide!

The ROS1ders Interview Dr. Ross Camidge

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

ROS1 News From Europe

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Thinking about a “drug vacation” from crizotinib? Read this first!

Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Crizotinib may be effective again after chemo

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)